Abstract 281P
Background
Tea industry is one of the oldest industries in India. In India the four main tea-producing states are Assam, West Bengal, Kerala and Tamil Nadu. Tea is also grown in parts of Tripura and Himachal Pradesh. There are more than one million workers in the tea industry in India comprising mainly of scheduled castes, tribes and ethnic minorities. Poor socio-economic conditions, ignorance due to illiteracy, over-crowded and unhygienic living conditions in the residential colonies make tea garden population vulnerable to various communicable diseases and malnutrition. This study was contemplated with an aim to assess the tobacco use and prevalence of premalignant lesions and oral cancer among tea plantation workers, Nilgiri Hills, Tamil Nadu, India.
Methods
A cross-sectional descriptive study was conducted to assess the tobacco use pattern, its frequency and type. Individual oral examination was done by a single examiner to check the premalignant lesions and oral cancer among tea plantation workers, Nilgiri Hills. Data was collected using a pretested Questionnaire, which included Demographic data, tobacco habits, its frequency and form. The data collected was analysed using SPSS version15.
Results
showed that among 400 study population from 5 tea estates, 46% had no formal education and 65% had indigenous brushing habits. 52% of oral mucosal lesions were detected, out of which most commonest was leukoplakia 34%, 42% tobacco pouch keratosis and 6% malignant oral tumours. Prevalence of oral mucosal lesions in the study population was due to tobacco usage and lack of awareness regarding the deleterious effects of the products used.
Conclusions
Tobacco use is a major preventable cause of premature deaths and diseases, the dangers from smoking and chewing tobacco are well documented within the literature but the public’s lack of knowledge of the risks is a concern. Health professionals are encouraged to ensure that the public is made aware of these risks.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
183P - Textbook outcome as a measure of surgical quality assessment and prognosis in gastric neuroendocrine carcinoma: A large multicenter sample analysis
Presenter: You-Xin Gao
Session: e-Poster Display Session
184P - Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric adenocarcinoma: An international multicenter study
Presenter: Bin-Bin Xu
Session: e-Poster Display Session
185P - Effect of sarcopenia on short- and long-term outcomes of patients with gastric neuroendocrine tumour after radical surgery: Results from a large, two-institutional series
Presenter: Ling-Qian Wang
Session: e-Poster Display Session
186P - Characterization of the gastroenteropancreatic neuroendocrine tumour patient journey
Presenter: George Fisher Jr
Session: e-Poster Display Session
187P - More is not always better: A multicenter study in lymphadenectomy during gastrectomy for gastric neuroendocrine carcinoma
Presenter: Qi-Yue Chen
Session: e-Poster Display Session
188P - The impact of sarcopenia on chemotherapy toxicity and survival rate among pancreatic cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Billy Susanto
Session: e-Poster Display Session
189P - Prognostic value of inflammation-based score for patients treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP)
Presenter: Takahiro Yamamura
Session: e-Poster Display Session
190P - Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
Presenter: Joon Oh Park
Session: e-Poster Display Session
191P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study
Presenter: Andrew Dean
Session: e-Poster Display Session
192P - A multicenter crossover analysis of first and second-line FOLFIRINOX or gemcitabine plus nab-paclitaxel administered to pancreatic cancer patients: Results from the NAPOLEON study
Presenter: Kenta Nio
Session: e-Poster Display Session